Who Buys Ivermectin from India — 712 Importers Behind a $8.7M Market

The 712 buyers of Ivermectin from India can be categorized into several segments:

1. Distributors: Entities that purchase Ivermectin in bulk to supply to various healthcare providers and retailers. For instance, REGENCY PHARMA LIMITED in Mauritius, the top buyer with imports totaling $2.46 million, likely operates as a distributor, given the substantial volume of their purchases. Distributors typically place large, periodic orders to maintain adequate stock levels and meet market demand.

2. Hospital Groups: These are networks of hospitals that procure medications directly for patient treatment. While specific hospital groups are not identified among the top 10 buyers, such entities generally order Ivermectin based on patient needs, leading to variable order sizes and frequencies.

3. Retail Chains: Pharmacy chains that purchase Ivermectin to stock their outlets. The data does not specify retail chains among the top buyers, but these entities usually place consistent orders to ensure continuous availability for consumers.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund procure Ivermectin for public health programs. Although not explicitly listed among the top buyers, such entities often engage in tender-based purchasing, resulting in large, scheduled orders aligned with programmatic needs.

5. Re-exporters: Companies that import Ivermectin with the intent to export it to other markets. EMIRATES POST COMPANY in the United Arab Emirates, with imports totaling $0.53 million, may function as a re-exporter, leveraging the UAE's strategic location as a global trade hub. Re-exporters typically order based on demand forecasts in their target export markets.

6. Contract Manufacturers: Firms that import Ivermectin as an active pharmaceutical ingredient (API) for formulation into finished products. While not explicitly identified among the top buyers, contract manufacturers usually place orders aligned with their production schedules and client demands.

The repeat buyer rate of 48.3% indicates a stable demand, with nearly half of the buyers returning for subsequent purchases, suggesting ongoing needs across these segments.

For the top five importing countries of Ivermectin from India, the import regulations are as follows:

The demand for Ivermectin in importing countries is influenced by several factors:

1. Disease Prevalence: Ivermectin is primarily used to treat parasitic infections such as onchocerciasis (river blindness) and lymphatic filariasis. Countries with high prevalence rates of these diseases, particularly in parts of Africa and Asia, exhibit substantial demand for Ivermectin.

2. Government Healthcare Programs: National health initiatives aimed at controlling and eliminating parasitic infections often include mass drug administration (MDA) campaigns utilizing Ivermectin. For example, the World Health Organization (WHO) has supported MDA programs in various endemic regions, contributing to increased procurement of Ivermectin.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in developing countries have led to increased access to essential medicines, including Ivermectin. As healthcare infrastructure improves, the demand for such medications rises correspondingly.

4. WHO Essential Medicines List Procurement: Ivermectin's inclusion in the WHO Essential Medicines List facilitates its procurement by governments and international organizations, ensuring its availability for public health programs.

5. Tender-Based Purchasing: Many countries and organizations procure pharmaceuticals through tender systems, which can lead to bulk purchasing of Ivermectin for national health programs. This method ensures cost-effectiveness and consistent supply for large-scale treatment initiatives.

The presence of 712 buyers across 140 countries indicates a widespread and sustained demand for Ivermectin, driven by these factors. This diverse buyer base presents ongoing market opportunities for suppliers.

The 712 buyers of Ivermectin from India can be categorized into several segments:

1. Distributors: Entities that purchase Ivermectin in bulk to supply to various healthcare providers and retailers. For instance, REGENCY PHARMA LIMITED in Mauritius, the top buyer with imports totaling $2.46 million, likely operates as a distributor, given the substantial volume of their purchases. Distributors typically place large, periodic orders to maintain adequate stock levels and meet market demand.

2. Hospital Groups: These are networks of hospitals that procure medications directly for patient treatment. While specific hospital groups are not identified among the top 10 buyers, such entities generally order Ivermectin based on patient needs, leading to variable order sizes and frequencies.

3. Retail Chains: Pharmacy chains that purchase Ivermectin to stock their outlets. The data does not specify retail chains among the top buyers, but these entities usually place consistent orders to ensure continuous availability for consumers.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund procure Ivermectin for public health programs. Although not explicitly listed among the top buyers, such entities often engage in tender-based purchasing, resulting in large, scheduled orders aligned with programmatic needs.

5. Re-exporters: Companies that import Ivermectin with the intent to export it to other markets. EMIRATES POST COMPANY in the United Arab Emirates, with imports totaling $0.53 million, may function as a re-exporter, leveraging the UAE's strategic location as a global trade hub. Re-exporters typically order based on demand forecasts in their target export markets.

6. Contract Manufacturers: Firms that import Ivermectin as an active pharmaceutical ingredient (API) for formulation into finished products. While not explicitly identified among the top buyers, contract manufacturers usually place orders aligned with their production schedules and client demands.

The repeat buyer rate of 48.3% indicates a stable demand, with nearly half of the buyers returning for subsequent purchases, suggesting ongoing needs across these segments.

For the top five importing countries of Ivermectin from India, the import regulations are as follows:

The demand for Ivermectin in importing countries is influenced by several factors:

1. Disease Prevalence: Ivermectin is primarily used to treat parasitic infections such as onchocerciasis (river blindness) and lymphatic filariasis. Countries with high prevalence rates of these diseases, particularly in parts of Africa and Asia, exhibit substantial demand for Ivermectin.

2. Government Healthcare Programs: National health initiatives aimed at controlling and eliminating parasitic infections often include mass drug administration (MDA) campaigns utilizing Ivermectin. For example, the World Health Organization (WHO) has supported MDA programs in various endemic regions, contributing to increased procurement of Ivermectin.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in developing countries have led to increased access to essential medicines, including Ivermectin. As healthcare infrastructure improves, the demand for such medications rises correspondingly.

4. WHO Essential Medicines List Procurement: Ivermectin's inclusion in the WHO Essential Medicines List facilitates its procurement by governments and international organizations, ensuring its availability for public health programs.

5. Tender-Based Purchasing: Many countries and organizations procure pharmaceuticals through tender systems, which can lead to bulk purchasing of Ivermectin for national health programs. This method ensures cost-effectiveness and consistent supply for large-scale treatment initiatives.

The presence of 712 buyers across 140 countries indicates a widespread and sustained demand for Ivermectin, driven by these factors. This diverse buyer base presents ongoing market opportunities for suppliers.